SXTP · 60 Degrees Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $162.1K | - | $437.6K | $100.9K | $163.6K | - | $135.3K | $125.0K | $116.5K | - |
| Cost of Revenue | $85.7K | - | $537.7K | $50.1K | $73.3K | - | $111.7K | $89.6K | $65.4K | - |
| Gross Profit | $76.4K | - | ($100.1K) | $50.9K | $90.3K | - | ($20.0K) | ($124.4K) | $51.0K | - |
| R&D | $281.5K | - | $809.8K | $249.9K | $407.6K | - | $940.1K | $3.10M | $337.2K | - |
| SG&A | $1.89M | - | $1.51M | $1.61M | $1.69M | - | $1.22M | $1.13M | $1.08M | - |
| Total Operating Expenses | $2.17M | - | $2.32M | $1.86M | $2.09M | - | $2.16M | $4.22M | $1.41M | - |
| D&A | $16.7K | - | $12.2K | $1.5K | $407 | - | $4.3K | $1.5K | $407 | - |
| Operating Income | ($2.09M) | - | ($2.33M) | ($1.60M) | ($1.91M) | - | ($2.12M) | ($4.19M) | ($1.33M) | - |
| Interest Expense | $1.4K | - | $1.7K | $1.2K | $1.4K | - | $0 | $0 | $1.4K | - |
| Income Tax | - | - | $250 | $1.5K | $63 | - | $250 | $438 | $63 | - |
| Net Income | ($2.09M) | - | ($2.32M) | ($1.73M) | ($1.88M) | - | ($2.16M) | ($4.17M) | $430.5K | - |
| EPS - Basic | ($1.28) | - | ($2.64) | ($5.00) | ($6.24) | - | ($18.60) | ($84.60) | $7.20 | - |
| EPS - Diluted | ($1.28) | - | ($2.64) | ($5.00) | ($6.24) | - | ($18.60) | ($84.60) | $7.20 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.34M | $1.51M | $4.12M | $1.97M | $3.45M | $1.66M | $3.30M | $1.58M | $30.0K | $2.14M |
| Accounts Receivable | $335.8K | $509.6K | $674.0K | $295.0K | $488.2K | $486.7K | $323.8K | $296.4K | $316.2K | $231.3K |
| Inventory | $910.6K | $656.9K | $527.0K | $799.4K | $773.2K | $442.8K | $452.0K | $426.0K | $435.4K | $466.2K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $6.26M | $4.90M | $6.31M | $3.84M | $5.65M | $5.39M | $6.89M | $3.76M | $7.91M | $7.24M |
| Total Assets | $6.76M | $5.37M | $6.69M | $4.18M | $5.98M | $5.76M | $7.42M | $4.33M | $8.38M | $7.78M |
| Current Liabilities | $1.88M | $1.84M | $2.20M | $1.69M | $1.80M | $1.66M | $1.31M | $1.22M | $1.10M | $2.84M |
| Long-term Debt | $150.0K | $144.0K | $150.0K | $150.0K | $150.0K | $147.1K | $150.0K | $150.0K | $150.0K | $150.0K |
| Total Liabilities | $2.02M | $1.99M | $2.34M | $1.84M | $1.95M | $1.80M | $1.46M | $1.37M | $1.25M | $2.99M |
| Stockholders' Equity | $4.83M | $3.46M | $4.43M | $2.43M | $4.11M | $4.04M | $6.04M | $3.04M | $7.20M | $4.87M |
| Retained Earnings | ($49.98M) | ($47.89M) | ($46.45M) | ($44.14M) | ($42.40M) | ($40.53M) | ($38.48M) | ($36.32M) | ($32.15M) | ($32.58M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.74M) | - | - | - | ($1.60M) | - | - | - | ($1.14M) | - |
| Investing Cash Flow | $1.19M | - | - | - | $1.70M | - | - | - | ($9.8K) | - |
| Financing Cash Flow | $3.37M | - | - | - | $1.70M | - | - | - | $1.90M | - |
| CapEx | $30.0K | - | - | - | $2.7K | - | - | - | - | - |
| Free Cash Flow | ($2.77M) | - | - | - | ($1.60M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 47.1% | - | -22.9% | 50.4% | 55.2% | - | -14.8% | -99.6% | 43.8% | - |
| Operating margin | -1292.5% | - | -531.4% | -1590.0% | -1168.4% | - | -1566.0% | -3351.8% | -1143.4% | - |
| EBITDA margin | -1282.1% | - | -528.6% | -1588.5% | -1168.1% | - | -1562.8% | -3350.5% | -1143.1% | - |
| Net margin | -1288.9% | - | -529.3% | -1717.7% | -1147.4% | - | -1596.4% | -3339.0% | 369.6% | - |
| Free cash flow margin | -1709.9% | - | - | - | -978.3% | - | - | - | - | - |
| FCF / Net income | 1.33 | - | - | - | 0.85 | - | - | - | - | - |
| R&D / Revenue | 173.6% | - | 185.0% | 247.6% | 249.2% | - | 694.8% | 2476.8% | 289.5% | - |
| SG&A / Revenue | 1165.9% | - | 344.3% | 1597.9% | 1031.0% | - | 898.1% | 903.9% | 923.2% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 0.0% | - |
| Return on assets | -30.9% | - | -34.6% | -41.5% | -31.4% | - | -29.1% | -96.4% | 5.1% | - |
| Return on equity | -43.3% | - | -52.3% | -71.4% | -45.7% | - | -35.8% | -137.5% | 6.0% | - |
| Return on invested capital | - | - | -40.1% | -49.2% | -35.4% | - | -27.0% | -103.9% | -18.1% | - |
| Liquidity | ||||||||||
| Current ratio | 3.34 | 2.66 | 2.87 | 2.27 | 3.13 | 3.25 | 5.26 | 3.09 | 7.16 | 2.55 |
| Quick ratio | 2.85 | 2.30 | 2.63 | 1.80 | 2.71 | 2.98 | 4.91 | 2.74 | 6.77 | 2.39 |
| Cash ratio | 1.78 | 0.82 | 1.87 | 1.16 | 1.91 | 1.00 | 2.52 | 1.29 | 0.03 | 0.76 |
| Leverage | ||||||||||
| Debt / Equity | 0.03 | 0.04 | 0.03 | 0.06 | 0.04 | 0.04 | 0.02 | 0.05 | 0.02 | 0.03 |
| Debt / Assets | 0.02 | 0.03 | 0.02 | 0.04 | 0.03 | 0.03 | 0.02 | 0.03 | 0.02 | 0.02 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1508.3x | - | -1361.5x | -1314.4x | -1363.0x | - | - | - | -949.8x | - |
| Equity multiplier | 1.40 | 1.55 | 1.51 | 1.72 | 1.45 | 1.43 | 1.23 | 1.43 | 1.16 | 1.60 |
| Liabilities / Assets | 0.30 | 0.37 | 0.35 | 0.44 | 0.33 | 0.31 | 0.20 | 0.32 | 0.15 | 0.38 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.07 | 0.02 | 0.03 | - | 0.02 | 0.03 | 0.01 | - |
| Inventory turnover | 0.09 | - | 1.02 | 0.06 | 0.09 | - | 0.25 | 0.21 | 0.15 | - |
| Days sales outstanding | 756d | - | 562d | 1067d | 1090d | - | 874d | 866d | 991d | - |
| Days inventory outstanding | 3878d | - | 358d | 5830d | 3852d | - | 1477d | 1736d | 2428d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 8.7x | - |
| P / B | 0.6x | - | 4.9x | 5.8x | 2.3x | - | 10.1x | 20.3x | 88.1x | - |
| P / S | 18.6x | - | 49.7x | 138.3x | 57.8x | - | 451.5x | 493.0x | 5445.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -0.9% | - | 223.4% | -19.2% | 40.4% | - | -19.6% | 109.9% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -15.4% | - | -400.2% | - | 76.9% | - | - | 0.0% | - | - |
| Operating income growth (YoY) | -9.6% | - | -9.8% | 61.7% | -43.5% | - | -39.2% | -431.6% | - | - |
| Net income growth (YoY) | -11.3% | - | -7.2% | 58.5% | - | - | -49.2% | -25.1% | - | - |
| EPS growth (YoY) | 79.5% | - | 85.8% | 94.1% | - | - | - | -8712.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -73.2% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 17.5% | -14.2% | -26.6% | -20.0% | -42.9% | -17.1% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$253.6K totalProduct Revenues$253.6K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing 60 DEGREES PHARMACEUTICALS against the 5 most active filers in the same SIC group.